Bristol-Myers Squibb Company

BMY

US1101221083

Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques. The United States account for 70.1% of net sales.

Sector

Pharmaceuticals

Calendar

26/07/2024 - Q2 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

Christopher Boerner, CEO of Bristol-Myers: A pipeline of 16 treatments, with a focus on neuroscience and oncology

January 09, 2024 at 06:06 pm

More Strategies

Ratings for Bristol-Myers Squibb Company

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

44.11 USD

Average target price

53.19 USD

Spread / Average Target

+20.60%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
BRISTOL-MYERS SQUIBB COMPANY	-14.03%	89.42B
ELI LILLY AND COMPANY	+32.36%	694B
NOVO NORDISK A/S	+29.71%	593B
JOHNSON & JOHNSON	-1.60%	371B
MERCK & CO., INC.	+20.07%	331B
ABBVIE INC.	+6.04%	290B
ASTRAZENECA PLC	+14.64%	239B
NOVARTIS AG	+10.18%	209B
ROCHE HOLDING AG	-3.27%	209B
AMGEN INC.	+9.27%	169B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 21:00:02 16/05/2024 BST			Pre-market 12:00:55
44.11 ^USD	-0.99%		44.26	+0.34%

05-16	Everlasting momentum
05-16	Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma	DJ

Everlasting momentum	05-16
Bristol Myers Gets FDA OK of Breyanzi in Follicular Lymphoma	05-16	DJ
Bristol-Myers Squibb Gets FDA Accelerated Approval for Breyanzi for Follicular Lymphoma	05-16	MT
Bristol Myers Squibb's CAR T Cell Therapy Breyanzi Approves by the U.S. Food and Drug Administration for Relapsed or Refractory Follicular Lymphoma	05-16	CI
US FDA approves expanded use of Bristol's cancer cell therapy	05-15	RE
Transcript : Bristol-Myers Squibb Company Presents at Bank of America Health Care Conference 2024, May-15-2024 11:20 AM	05-15
Transcript : Bristol-Myers Squibb Company Presents at Guggenheim Securities Radiopharmaceuticals Day, May-13-2024 11:00 AM	05-13
Bristol-Myers Squibb Says Phase 3 Trial of Opdivo in Lung Cancer Fails to Meet Primary Endpoint	05-10	MT
Bristol Myers Squibb Cancer-Treatment Trial Misses Endpoint	05-10	DJ
Bristol Myers Squibb Provides Update on Phase 3 CheckMate -73L Trial	05-10	CI
India's Cipla open to partnering with Eli Lilly to market their obesity drugs, CEO says	05-10	RE
Declaration of Voting Results by Bristol-Myers Squibb Company	05-09	CI
Declaration of Voting Results by Bristol-Myers Squibb Company	05-09	CI
India's Alembic Pharma posts higher Q4 profit on strong N.America sales	05-09	RE
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	05-07	MT
Top Midday Stories: Tyson Shares Tumble on Earnings Miss; Robinhood Receives Wells Notice From SEC Staff; Spirit Airlines to Furlough up to 260 Pilots; Shell in Talks to Sell Malaysian Gas Station Business to Saudi Aramco	05-06	MT
Bristol-Myers Squibb Says Applications for Opdivo Accepted by US, European Regulators	05-06	MT
Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation	05-06	DJ
Bristol-Myers: BLA accepted for subcutaneous Opdivo	05-06	CF
U.S. Food and Drug Administration Accepts Bristol Myers Squibb?s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)	05-06	CI
European Medicines Agency Validates Bristol Myers Squibb?s Application for Opdivo Plus Yervoy for the First-Line Treatment of Adult Patients with Microsatellite Instability?High or Mismatch Repair Deficient Metastatic Colorectal Cancer	05-06	CI
HSBC Adjusts Price Target on Bristol-Myers Squibb to $45 From $50	05-01	MT
Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	05-01	MT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	05-01	CI
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla...	04-30